Vertex Pharmaceuticals Incorporated (VRTX) Stock Overview
Explore Vertex Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Vertex Pharmaceuticals Incorporated (VRTX)
Key Financials
Key Financials
Market Cap
113.4B
P/E Ratio
26.15
EPS (TTM)
$16.83
ROE
0.24%
VRTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Vertex Pharmaceuticals Incorporated (VRTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 54.75, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $540.09.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 26.15 and a market capitalization of 113.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.